Platinum-induced neurotoxicity and preventive strategies: Past, present, and future

Oncologist

Volumn 20, Issue 4, 2015, Pages 411-432

  Avan, Abolfazl ^a   Postma, Tjeerd J ^a   Ceresa, Cecilia ^b   Avan, Amir ^a,c   Cavaletti, Guido ^b   Giovannetti, Elisa ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Models; Neurotoxicity; Pathogenesis; Platinum; Polymorphism; Prevention

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; CARBOPLATIN; CHELATING AGENT; CISPLATIN; ELECTROLYTE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; OXALIPLATIN; PLATINUM; RETINOIC ACID; SODIUM THIOSULFATE; VOLTAGE GATED SODIUM CHANNEL; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

APOPTOSIS; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DNA ADDUCT; DNA REPAIR; ENZYME IMMOBILIZATION; HUMAN; META ANALYSIS (TOPIC); NEUROPROTECTION; NEUROTOXICITY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; GENETIC POLYMORPHISM; NEUROTOXICITY SYNDROMES;

ANTINEOPLASTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PHARMACOGENETICS; PLATINUM COMPOUNDS; POLYMORPHISM, GENETIC;

EID: 84927610343     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0044     Document Type: Article

References (206)

1. Fuertes MA, Castilla J, Alonso C et al. Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anticancer Agents 2002; 2: 539-551.
2. Boulikas T, Pantos A, Bellis E et al. Designing platinum compounds in cancer: Structures and mechanisms. Cancer Ther 2007; 5: 537-583.
3. Pichler V, Mayr J, Heffeter P et al. Maleimidefunctionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. Chem Commun (Camb) 2013; 49: 2249-2251.
4. Ali I, Wani WA, Saleem K et al. Platinum compounds: A hope for future cancer chemotherapy. Anticancer Agents Med Chem 2013; 13: 296-306.
5. Argyriou AA, Bruna J, Marmiroli P et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 2012; 82: 51-77.
6. Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know. J Peripher Nerv Syst 2014; 19: 66-76.
7. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126-127.
8. Prestayko AW, D'Aoust JC, Issell BF et al. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 1979; 6: 17-39.
9. Albers JW, Chaudhry V, Cavaletti G et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014; 3: CD005228.
10. de Castria TB, da Silva EM, Gois AF et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013; 8: CD009256.
11. Ibrahim A, Hirschfeld S, Cohen MH et al. FDA drug approval summaries: Oxaliplatin. The Oncologist 2004; 9: 8-12.
12. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
13. Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003; 30(suppl 15): 5-13.
14. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004; 5: 2159-2170.
15. Argyriou AA, Briani C, Cavaletti G et al. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: Post hoc analysis of a prospective study. Eur J Neurol 2013; 20: 788-794.
16. Argyriou AA, Cavaletti G, Briani C et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer 2013; 119: 438-444.
17. Argyriou AA, Velasco R, Briani C et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012; 23: 3116-3122.
18. Park SB, Lin CS, Krishnan AV et al. Oxaliplatininduced neurotoxicity: Changes in axonal excitability precede developmentof neuropathy. Brain 2009; 132: 2712-2723.
19. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011; 12: 1151-1161.
20. Argyriou AA, Cavaletti G, Antonacopoulou A et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatininduced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 2013; 119: 3570-3577.
21. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2014; 7: CD009219.
22. McHaney VA, Thibadoux G, Hayes FA et al. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983; 102: 314-317.
23. Bertolini P, Lassalle M, Mercier G et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
24. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-244.
25. Brydøy M, Oldenburg J, Klepp O et al. Observational study of prevalence of long-term Raynaudlike phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101: 1682-1695.
26. Thomas JP, Lautermann J, Liedert B et al. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 2006; 70: 23-29.
27. Verstappen CC, Heimans JJ, Hoekman K et al. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003; 63: 1549-1563.
28. Hill A, Bergin P, Hanning F et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010; 10: 451.
29. Wilson RH, Lehky T, Thomas RR et al. Acute oxaliplatin-inducedperipheralnerve hyperexcitability. J Clin Oncol 2002; 20: 1767-1774.
30. Krishnan AV, Goldstein D, Friedlander M et al. Oxaliplatin and axonal Na1channel function in vivo. Clin Cancer Res 2006; 12: 4481-4484.
31. Cavaletti G, Alberti P, Frigeni B et al. Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011; 13: 180-190.
32. Alberti P, Rossi E, Cornblath DRet al. Physicianassessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Ann Oncol 2014; 25: 257-264.
33. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. JNatl Cancer Inst 1993; 85: 1138-1148.
34. Koeppen S, VerstappenCC, KörteRet al. Lackof neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 2004; 130: 153-160.
35. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998; 9: 739-744.
36. Inoue N, Ishida H, Sano M et al. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 2012; 17: 341-347.
37. Sprowl JA, Ciarimboli G, Lancaster CS et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 2013; 110: 11199-11204.
38. Jong NN, Nakanishi T, Liu JJ et al. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 2011; 338: 537-547.
39. IpV, Liu JJ, McKeageMJ. Evaluation ofeffects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol 2013; 40: 371-378.
40. Liu JJ, KimY, YanF et al. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol 2013; 85: 207-215.
41. Ishida S, Lee J, Thiele DJ et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-14302.
42. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006; 234: 34-39.
43. Guminski AD, Balleine RL, Chiew YE et al. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 2006; 100: 239-246.
44. Ip V, Liu JJ, Mercer JF et al. Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol Pain 2010; 6: 53.
45. Yamasaki M, Makino T, Masuzawa T et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 2011; 104: 707-713.
46. Zhu C, Raber J, Eriksson LA. Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II). J Phys Chem B 2005; 109: 12195-12205.
47. Chválová K, Brabec V, Kaspárková J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007; 35: 1812-1821.
48. McDonald ES, Randon KR, Knight A et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol Dis 2005; 18: 305-313.
49. Dzagnidze A, Katsarava Z, Makhalova J et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007; 27: 9451-9457.
50. Ta LE, Espeset L, Podratz J et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27: 992-1002.
51. Gregg RW, Molepo JM, Monpetit VJ et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
52. McKeage MJ, Hsu T, Screnci D et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001; 85: 1219-1225.
53. Namikawa K, Asakura M, Minami T et al. Toxicity of cisplatin to the central nervous system of male rabbits. Biol Trace Elem Res 2000; 74: 223-235.
54. Olivi A, Gilbert M, Duncan KL et al. Direct delivery of platinum-based antineoplastics to the central nervous system: A toxicity and ultrastructural study. Cancer Chemother Pharmacol 1993; 31: 449-454.
55. Adelsberger H, Quasthoff S, Grosskreutz J et al. The chemotherapeutic oxaliplatin alters voltagegated Na1 channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25-32.
56. Grolleau F, Stankiewicz M, Birinyi-Strachan L et al. Electrophysiological analysis of the neurotoxic action of a funnel-web spider toxin, deltaatracotoxin-HV1a, on insect voltage-gated Na1 channels. J Exp Biol 2001; 204: 711-721.
57. Sittl R, Lampert A, Huth T et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1. 6-resurgent and persistent current. Proc Natl Acad Sci USA 2012; 109: 6704-6709.
58. Dimitrov VG, Arabadzhiev TI, Dimitrova NA et al. The spectral changes in EMG during a second bout eccentric contraction could be due to adaptation in muscle fibres themselves: Asimulation study. Eur J Appl Physiol 2012; 112: 1399-1409.
59. Kagiava A, Tsingotjidou A, Emmanouilides C et al. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheralmyelinated nerve fibres of the adult rat. Neurotoxicology 2008; 29: 1100-1106.
60. Mogyoros I, Lin CS, Kuwabara S et al. Strengthduration properties and their voltage dependence as measures of a threshold conductance at the node of Ranvier of single motor axons. Muscle Nerve 2000; 23: 1719-1726.
61. Raymond E, Chaney SG, Taamma A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071.
62. Podratz JL, Knight AM, Ta LE et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011; 41: 661-668.
63. Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in nonsmall cell lung cancer patients. Clin Cancer Res2005; 11: 1534-1538.
64. Argyriou AA, Kyritsis AP, Makatsoris T et al. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Manag Res 2014; 6: 135-147.
65. Bergmann TK, Gréen H, Brasch-Andersen C et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67: 693-700.
66. Gréen H, Söderkvist P, Rosenberg P et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009; 104: 130-137.
67. Marsh S, Paul J, King CR et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25: 4528-4535.
68. McLeod HL, Sargent DJ, Marsh S et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal IntergroupTrialN9741. J ClinOncol2010; 28: 3227-3233.
69. Cecchin E, D'Andrea M, Lonardi S et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 2013; 13: 403-409.
70. Custodio A, Moreno-Rubio J, Aparicio J et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study. Ann Oncol 2014; 25: 398-403.
71. Won HH, Lee J, Park JO et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 2012; 118: 2828-2836.
72. Gamelin L, Capitain O, Morel A et al. Predictive factors ofoxaliplatin neurotoxicity: Theinvolvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13: 6359-6368.
73. Lee KH, Chang HJ, Han SW et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol 2013; 71: 843-851.
74. Inada M, Sato M, Morita S et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010; 48: 729-734.
75. Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean populationbased study. Gynecol Oncol 2009; 113: 264-269.
76. Fung C, Vaughn DJ, Mitra N et al. Chemotherapy refractory testicular germ cell tumor is associated with avariant in Armadillo Repeatgenedeleted in Velco-Cardio-Facial syndrome (ARVCF). Front Endocrinol (Lausanne) 2012; 3: 163.
77. Hong J, Han SW, Ham HS et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy inmetastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 2011; 67: 1323-1331.
78. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28: 2556-2564.
79. Caponigro F, Lacombe D, Twelves C et al. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 2009; 45: 48-55.
80. Chen YC, Tzeng CH, Chen PM et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2010; 101: 530-535.
81. Goekkurt E, Al-Batran SE, Hartmann JT et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft InternistischeOnkologie. J ClinOncol2009; 27: 2863-2873.
82. Isla D, Sarries C, RosellRet al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatintreated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
83. KeamB, ImSA, HanSWet al. ModifiedFOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008; 8: 148.
84. Khrunin AV, Moisseev A, Gorbunova V et al. Genetic polymorphisms and the efficacy and toxicityof cisplatin-based chemotherapy inovarian cancer patients. Pharmacogenomics J 2010; 10: 54-61.
85. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247-1254.
86. Seo BG, Kwon HC, Oh SY et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOXor FOLFIRI. Oncol Rep2009; 22: 127-136.
87. Zarate R, Rodríguez J, Bandres E et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis. Br J Cancer 2010; 102: 987-994.
88. Kumamoto K, Ishibashi K, Okada N et al. Polymorphisms of GSTP1, ERCC2 and TS-39UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett 2013; 6: 648-654.
89. Lecomte T, Landi B, Beaune P et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050-3056.
90. Oldenburg J, Kraggerud SM, Brydøy M et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-S-transferase-P1 and-M1, a retrospective cross sectional study. J TranslMed 2007; 5: 70.
91. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-942.
92. Antonacopoulou AG, Argyriou AA, Scopa CD et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 2010; 17: 963-968.
93. Li QF, Yao RY, Liu KW et al. Genetic polymorphism of GSTP1: Prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 2010; 25: 846-852.
94. Kanai M, Yoshioka A, Tanaka S et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11-Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 2010; 34: 189-193.
95. Booton R, Ward T, Heighway J et al. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and nonsmall cell lung cancer. J Thorac Oncol 2006; 1: 679-683.
96. Kweekel DM, Gelderblom H, Antonini NF et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009; 45: 572-578.
97. Par é L, Marcuello E, Alt és A et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99: 1050-1055.
98. Argyriou AA, Antonacopoulou AG, Scopa CD et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatininduced peripheral neuropathy. Oncology 2009; 77: 254-256.
99. Ashraf T, Kis O, Banerjee N et al. Drug transporters at brain barriers: Expression and regulation by neurological disorders. Adv Exp Med Biol 2012; 763: 20-69.
100. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
101. Lolli G, Johnson LN. CAK-cyclin-dependent activating kinase: A key kinase in cell cycle control and a target for drugs? Cell Cycle 2005; 4: 572-577.
102. Wu G, Cao J, PengCet al. Temporal and spatial expression of cyclin H in rat spinal cord injury. Neuromolecular Med 2011; 13: 187-196.
103. Weinshilboum RM. Pharmacogenomics: Catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol 2006; 26: 539-561.
104. Ross CJ, Katzov-Eckert H, Dubé MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
105. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013; 94: 243-251.
106. Peng Z, Wang Q, Gao J et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: A systematic review and meta-analysis. Cancer Chemother Pharmacol 2013; 72: 305-314.
107. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31: 90-105.
108. Zhang X, Jiang LP, Yin Y et al. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatinbased chemotherapy: Ameta-analysis. Tumour Biol 2014; 35: 5637-5645.
109. Ségurel L, Lafosse S, Heyer E et al. Frequency of the AGT Pro11Leu polymorphism in humans: Does diet matter? Ann Hum Genet 2010; 74: 57-64.
110. Cavaletti G, Miloso M, Nicolini G et al. Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J Peripher Nerv Syst 2007; 12: 175-194.
111. Bianchi R, Gilardini A, Rodriguez-Menendez V et al. Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 2007; 43: 710-717.
112. Cavaletti G, Gilardini A, Canta A et al. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317-325.
113. Meregalli C, Canta A, Carozzi VA et al. Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010; 14: 343-350.
114. Müller LJ, Moorer-van Delft CM, Roubos EW. Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: Paracrystal formation by Vinca alkaloids. Cancer Res 1988; 48: 7184-7188.
115. Müller LJ, Moorer-van Delft CM, Roubos EW et al. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis. Cancer Res 1992; 52: 963-973.
116. Müller LJ, Moorer-van Delft CM, Zijl R et al. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents. Cancer Res 1990; 50: 1924-1928.
117. DiPaola RS, Schuchter L. Neurologic protection by amifostine. Semin Oncol 1999; 26(suppl 7): 82-88.
118. Geldof AA. Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 1995; 121: 657-660.
119. Geldof AA, Minneboo A, Heimans JJ. Vincaalkaloid neurotoxicity measured using an in vitro model. J Neurooncol 1998; 37: 109-113.
120. Verstappen CC, Geldof AA, Postma TJ et al. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metaboliteWR1065. J Neurooncol 1999; 44: 1-5.
121. Verstappen CC, Postma TJ, Geldof AA et al. Amifostine protects against chemotherapy-induced neurotoxicity: An in vitro investigation. Anticancer Res 2004; 24: 2337-2341.
122. Ceresa C, Avan A, Giovannetti E et al. Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. Anticancer Res 2014; 34: 517-523.
123. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapyinduced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-1967.
124. Lin CH, Kuo SC, Huang LJ et al. Neuroprotective effect of N-acetylcysteine on neuronal apoptosis induced by a synthetic gingerdione compound: Involvement of ERK and p38 phosphorylation. J Neurosci Res 2006; 84: 1485-1494.
125. Guo Y, Jones D, Palmer JL et al. Oral alphalipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014; 22: 1223-1231.
126. Lu P, Fan QX, Wang LX et al. [Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors]. Ai Zheng 2008; 27: 1117-1120.
127. De Vos FY, Bos AM, Schaapveld M et al. A randomized phase II study of paclitaxel with carboplatin 1/2 amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005; 97: 60-67.
128. Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy: A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13: 797-805.
129. Kanat O, Evrensel T, Baran I et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study. Med Oncol 2003; 20: 237-245.
130. Leong SS, Tan EH, FongKWet al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003; 21: 1767-1774.
131. Lorusso D, Ferrandina G, Greggi S et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003; 14: 1086-1093.
132. Gallardo D, Mohar A, Calderillo G et al. Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix. Int J Gynecol Cancer 1999; 9: 225-230.
133. Planting AS, Catimel G, de Mulder PH et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999; 10: 693-700.
134. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamideinduced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-2112.
135. Miller AA, Wang XF, Gu L et al. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced nonsmall cell lung cancer (CALGB 30303). J Thorac Oncol 2008; 3: 1159-1165.
136. Han CH, Khwaounjoo P, Kilfoyle DH et al. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer 2013; 13: 495.
137. Loprinzi CL, Qin R, Dakhil SR et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014; 32: 997-1005.
138. Grothey A, Nikcevich DA, Sloan JA et al. Intravenous calcium and magnesium for oxaliplatininduced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-427.
139. Knijn N, Tol J, Koopman M et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome ofoxaliplatin-basedsystemic treatmentin advanced colorectal cancer patients. Eur J Cancer 2011; 47: 369-374.
140. Ishibashi K, OkadaN, Miyazaki T et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 2010; 15: 82-87.
141. Chay WY, Tan SH, Lo YL et al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. AsiaPac J Clin Oncol 2010; 6: 270-277.
142. von Delius S, Eckel F, Wagenpfeil S et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25: 173-180.
143. Gandara DR, Nahhas WA, Adelson MD et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13: 490-496.
144. WangWS, Lin JK, Lin TC et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist 2007; 12: 312-319.
145. Leal AD, Qin R, Atherton PJ et al. North Central Cancer Treatment Group/Alliance trial N08CA: The use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebocontrolled study. Cancer 2014; 120: 1890-1897.
146. Milla P, Airoldi M, Weber G et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: Effect onoxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 2009; 20: 396-402.
147. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483.
148. Schmidinger M, Budinsky AC, Wenzel C et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr 2000; 112: 617-623.
149. Smyth JF, Bowman A, Perren T et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial. Ann Oncol 1997; 8: 569-573.
150. Cascinu S, Cordella L, Del Ferro E et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebocontrolled trial. J Clin Oncol 1995; 13: 26-32.
151. Colombo N, Bini S, Miceli D et al. Weekly cisplatin 1/2 glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 81-86.
152. Bogliun G, Marzorati L, Cavaletti G et al. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Ital J Neurol Sci 1992; 13: 643-647.
153. Kono T, Hata T, Morita S et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 2013; 72: 1283-1290.
154. Nishioka M, Shimada M, Kurita N et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 2011; 16: 322-327.
155. Cassidy J, Paul J, SoukopMet al. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 1998; 41: 161-166.
156. Roberts JA, Jenison EL, Kim K et al. A randomized, multicenter, double-blind, placebocontrolled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67: 172-177.
157. van Gerven JM, Hovestadt A, Moll JW et al. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial. J Neurol 1994; 241: 432-435.
158. Hovestadt A, van der Burg ME, Verbiest HB et al. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 1992; 239: 143-146.
159. van der Hoop RG, Vecht CJ, van der Burg ME et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94.
160. Argyriou AA, Chroni E, Polychronopoulos P et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006; 67: 2253-2255.
161. Arrieta O, García-Navarrete R, Zúñiga S et al. Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. Eur J Clin Invest 2005; 35: 201-207.
162. Davis ID, Kiers L, MacGregor L et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005; 11: 1890-1898.
163. Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebocontrolled phase III trial. Ann Oncol 2012; 23: 200-205.
164. Kottschade LA, Sloan JA, MazurczakMA et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 2011; 19: 1769-1777.
165. Pace A, Giannarelli D, Galiè E et al. Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology 2010; 74: 762-766.
166. Argyriou AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: Final results. Support Care Cancer 2006; 14: 1134-1140.
167. Pace A, Savarese A, Picardo M et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003; 21: 927-931.
168. Cassidy J, Bjarnason GA, Hickish T et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in firstline treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2006; 24 (suppl 18): 3507a.
169. Harned TM, Kalous O, Neuwelt A et al. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res 2008; 14: 533-540.
170. Muldoon LL, Pagel MA, Kroll RA et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 2000; 6: 309-315.
171. DickeyDT, Wu YJ, Muldoon LL et al. Protection against cisplatin-induced toxicities by Nacetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314: 1052-1058.
172. Maibach R, Childs M, Rajput K et al. SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB). J Clin Oncol 2014; 32(suppl 5): TPS10094a.
173. Freyer DR. The effects of sodium thiosulfate (STS) on cisplatin-induced hearing loss: A report from the Children's Oncology Group. J Clin Oncol 2014; 32(suppl 5): 10017a.
174. Parker AR, Petluru PN, WuMet al. BNP7787-mediated modulation of paclitaxel-and cisplatininduced aberrant microtubule protein polymerization in vitro. Mol Cancer Ther 2010; 9: 2558-2567.
175. De Santis S, Pace A, Bove L et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000; 6: 90-95.
176. Schmidt Y, Unger JW, Bartke I et al. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995; 132: 16-23.
177. Scuteri A, Galimberti A, Ravasi M et al. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett 2010; 486: 141-145.
178. Corcoran J, Maden M. Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth. Nat Neurosci 1999; 2: 307-308.
179. Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-inducedneuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41: 1746-1750.
180. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: A short review. CNS Drugs 2007; 21 (suppl 1): 39-46.
181. Ghirardi O, Lo Giudice P, Pisano C et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005; 25: 2681-2687.
182. Gwag BJ, Sessler FM, Robine V et al. Endogenous glutamatelevels regulatenervegrowthfactor mRNA expression in the rat dentate gyrus. Mol Cells 1997; 7: 425-430.
183. Taglialatela G, Navarra D, Cruciani R et al. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol 1994; 29: 55-66.
184. Bianchi R, Brines M, Lauria G et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006; 12: 2607-2612.
185. LeistM, Ghezzi P, GrassoGet al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
186. Arrieta Ó, Hernández-Pedro N, Fernández-González-Arag ón MC et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 2011; 77: 987-995.
187. Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arh 2013; 67: 7-9.
188. Barhwal K, Hota SK, Prasad D et al. Hypoxiainduced deactivation of NGF-mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl-L-carnitine. J Neurosci Res 2008; 86: 2705-2721.
189. Gopal KV, Wu C, Shrestha B et al. DMethionine protects against cisplatin-induced neurotoxicity in cortical networks. Neurotoxicol Teratol 2012; 34: 495-504.
190. Schmutz M, Brugger F, Gentsch C et al. Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35(suppl 5): S47-S50.
191. Barhwal K, Hota SK, Jain V et al. Acetyl-Lcarnitine (ALCAR) prevents hypobaric hypoxiainduced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation. Neuroscience 2009; 161: 501-514.
192. Hershman DL, Unger JM, Crew KD et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxaneinduced neuropathyinwomenundergoingadjuvant breast cancer therapy. J Clin Oncol 2013; 31: 2627-2633.
193. Susman E. Xaliproden lessens oxaliplatinmediated neuropathy. Lancet Oncol 2006; 7: 288.
194. Nagaki Y, Hayasaka S, Hayasaka Y et al. Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus. AmJ Chin Med 2003; 31: 103-109.
195. Kono T, Mishima H, Shimada M et al. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: A placebocontrolled double-blind randomized phase II study (the GONE Study). Jpn J Clin Oncol 2009; 39: 847-849.
196. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-oncol 2012; 14(suppl 4): iv45-iv54.
197. Kaur G, Phillips C, Wong K et al. Timing is important in medication administration: A timely review of chronotherapy research. Int J Clin Pharmacol 2013; 35: 344-358.
198. Mormont MC, Lévi F. Circadian-system alterations during cancer processes: A review. Int J Cancer 1997; 70: 241-247.
199. Liao C, Li J, Bin Q et al. Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: A meta-analysis of five randomized controlled trials. Int J Colorectal Dis 2010; 25: 343-350.
200. Cavaletti G. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity? The Oncologist 2011; 16: 1667-1668.
201. Khattak MA. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity? The Oncologist 2011; 16: 1780-1783.
202. Smith EM, Pang H, Cirrincione C et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013; 309: 1359-1367.
203. Hammack JE, Michalak JC, Loprinzi CL et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98: 195-203.
204. Rao RD, Michalak JC, Sloan JA et al. Efficacy of gabapentin in the management of chemotherapyinduced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110: 2110-2118.
205. Rao RD, Flynn PJ, Sloan JA et al. Efficacy of lamotrigine in the management of chemotherapyinduced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112: 2802-2808.
206. Barton DL, Wos EJ, Qin R et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011; 19: 833-841.